Evidera
Mark Yates is an accomplished professional in the field of rheumatology and epidemiology, currently serving as a Research Scientist and Associate Director at Evidera since July 2022, where real-world data analytics and consultancy is a focus. Additionally, Mark holds the position of Honorary Lecturer at King's College London within the Centre for Rheumatic Disease. Previously, Mark was the Director of Epidemiology at Our Future Health UK, where expertise contributed to a resource aimed at early disease detection. As a Clinical Research Fellow at King's College London from August 2016 to September 2021, Mark led significant research efforts in various aspects of inflammatory arthritis and COVID-19. Mark's medical career began with experience as a medical doctor in rheumatology within the NHS, complemented by a comprehensive educational background that includes a PhD in Rheumatology from King's College London, an MBChB from The University of Manchester, and membership in the Royal College of Physicians.
This person is not in any offices
Evidera
1 followers
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.